Suppliers and packagers for JEVTANA KIT

JEVTANA KIT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sanofi Aventis Us	JEVTANA KIT	cabazitaxel	SOLUTION;INTRAVENOUS	201023	NDA	Sanofi-Aventis U.S. LLC	0024-5824-11	1 KIT in 1 CARTON (0024-5824-11) * 5.7 mL in 1 VIAL, GLASS (0024-5823-15) * 5.7 mL in 1 VIAL, GLASS (0024-5822-01)	2010-06-17

Suppliers for the Pharmaceutical Drug: JEVTANA KIT

Last updated: August 9, 2025

---

Introduction

The pharmaceutical landscape continually evolves with the introduction of targeted therapies for cancer treatment. One notable example is Jevtana Kit (cabazitaxel), a chemotherapeutic agent used predominantly in prostate cancer management. As the demand for this drug grows globally, understanding the supplier ecosystem becomes crucial for stakeholders—including healthcare providers, distributors, and investors—aiming to ensure consistent availability and proper supply chain management. This comprehensive analysis examines the primary suppliers of Jevtana Kit, evaluating manufacturing sources, distribution channels, and strategic partnerships underpinning its market supply.

---

Overview of Jevtana Kit and Its Market Significance

Jevtana Kit contains cabazitaxel encapsulated for injection, combined with necessary diluents. Approved by regulatory authorities such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency), Jevtana addresses metastatic castration-resistant prostate cancer (mCRPC), especially after chemotherapy failure. The drug's proprietary formulation and manufacturing complexity position its supply heavily on specialized suppliers and manufacturing partners.

---

Manufacturers of Cabazitaxel

Since its inception, the primary manufacturer for cabazitaxel, including Jevtana Kit, has been Sanofi (Sanofi-Aventis), which acquired exclusive rights for the drug's production and distribution when it was approved.

Sanofi

• Role: Sole global manufacturer of cabazitaxel, including Jevtana Kit.
• Manufacturing Facilities: Sanofi operates high-capacity, cGMP-compliant manufacturing units primarily located in Europe and North America, including sites in France and the United States.
• Supply Chain Control: As the patent and manufacturing rights are held by Sanofi, the company controls the entire supply chain, minimizing dependency on third-party suppliers.

Key Point: Sanofi’s dominance in manufacturing makes it the central supplier for Jevtana Kit; thus, procurement efforts are heavily reliant on Sanofi’s production capacity and distribution policies.

---

Licensing and Strategic Manufacturing Partnerships

Throughout its commercialization, Sanofi has engaged in licensing agreements to diversify manufacturing capacity subtly and mitigate risks such as supply disruptions. No significant third-party licensed manufacturing of cabazitaxel for Jevtana Kit is publicly documented, making Sanofi the primary and perhaps sole ongoing producer.

---

Distribution Channels and Supply Chain Management

Once manufactured, Sanofi distributes Jevtana Kit through a combination of:

• Direct Global Distribution: Sanofi maintains a network of regional distribution centers that supply hospitals and specialty pharmacies.
• Third-Party Logistics (3PL) Providers: Sanofi partners with logistics firms to ensure cold chain integrity and timely delivery.
• Regional Distributors: In certain markets, especially in emerging economies, regional distributors act as intermediaries, relying on Sanofi’s shipments.

Note: Supply constraints or production delays at Sanofi impact availability worldwide, emphasizing the importance of reliable partnerships and inventory management.

---

Regional Suppliers and Market-specific Considerations

While Sanofi remains the principal manufacturer:

• United States: Direct procurement from Sanofi via authorized distributors.
• Europe: Distributed through Sanofi's European subsidiaries.
• Asia and Africa: Sanofi leverages regional licensing agreements; some markets may have local importers or authorized wholesalers authorized to distribute Jevtana Kit.

Import Regulations and Pricing Dynamics: Local regulatory hurdles and pricing policies influence supplier selection and availability. In some markets, generic or biosimilar alternatives are absent; thus, Sanofi’s supply stability becomes critical.

---

Potential for Generic and Biosimilar Competition

Although Sanofi holds the original patent and manufacturing rights, patent expirations could eventually introduce generic cabazitaxel options, increasing supplier diversity. No approved biosimilars or generics currently exist for cabazitaxel, but industry developments suggest future competitiveness.

Implication: Once generics enter the market, multiple suppliers could emerge, potentially lowering costs and expanding supply options.

---

Supply Chain Risks and Strategic Considerations

• Manufacturing Disruptions: Sanofi’s sole manufacturing status positions it as a single point of failure.
• Regulatory Actions: Changes in licensing or regulatory approvals could affect supply availability.
• Demand Fluctuations: Increasing global incidence of prostate cancer could strain Sanofi’s manufacturing capacity.

Mitigation Strategies: Stakeholders should diversify sources upon market entry of generics and establish robust inventory management protocols.

---

Conclusion

The primary supplier for Jevtana Kit is Sanofi, which maintains exclusive manufacturing rights and controls global distribution. No significant second-tier suppliers or manufacturers currently contribute to its supply chain, underscoring Sanofi’s critical role. However, market dynamics, regulatory environments, and patent expirations could alter this landscape, fostering potential new entry points for competitors. Careful supply chain management and close monitoring of patent transitions are essential to ensure reliable access and cost containment.

---

Key Takeaways

• Sanofi is the exclusive manufacturer and primary supplier of Jevtana Kit globally.
• The supply chain relies heavily on Sanofi's manufacturing capacity, with limited alternative sources.
• Distribution channels involve direct Sanofi logistics, regional distributors, and third-party logistics providers.
• Future market entries of biosimilars and generics could diversify supplier options, reducing reliance on Sanofi.
• Stakeholders should monitor patent statuses and regulatory developments to mitigate supply risks.

---

FAQs

1. Who manufactures Jevtana Kit globally?
Sanofi is the sole manufacturer and supplier of Jevtana Kit worldwide, holding exclusive rights for production and distribution.

2. Are there any approved generic versions of cabazitaxel?
As of 2023, no approved generics or biosimilars for cabazitaxel exist; Sanofi maintains exclusive rights.

3. What risks are associated with relying on a single supplier for Jevtana Kit?
Dependence on Sanofi poses risks such as manufacturing disruptions, supply shortages, and price fluctuations, especially if patent protections are maintained.

4. Could new suppliers enter the market in the future?
Yes. Patent expirations and regulatory approvals could enable generic manufacturers to produce cabazitaxel, diversifying supply options.

5. How can healthcare providers ensure consistent Jevtana Kit supply?
Proactive inventory management, establishing relationships with authorized distributors, and monitoring patent and regulatory developments are vital strategies.

---

References

1. FDA Approval of Jevtana: U.S. Food and Drug Administration. (2010). Jevtana (cabazitaxel) approval letter.
2. Sanofi Cabazitaxel Manufacturing: Sanofi official website and press releases.
3. European Medicines Agency: CEPs and regulatory filings of Jevtana.
4. Market Reports: IMS Health, EvaluatePharma data on prostate cancer therapeutics.
5. Patent and Biosimilar News: WHO Global Art & Patent Database, biosimilar development updates.